win ratio: the CanCovDia study

dossier: me20Donath2

services: .consulting (Alexandra, Sina)
.regulatory (David, Claudia, Bettina, Kristin)
.statistics (Marco)

Canakinumab in patients with COVID-19 and type 2 diabetes — A multicentre, randomised, double-blind, placebo-controlled trial

Matthias Hepprich,[a,1] Jonathan M. Mudry,[a,1] Claudia Gregoriano,[b] Francois R. Jornayvaz,[j] Sebastian Carballo,[i]
Anne Wojtusciszyn,[l] Pierre-Alexandre Bart,[g] Jean-Daniel Chiche,[k] Stefan Fischli,[h] Thomas Baumgartner,[m] Claudia Cavelti-Weder,[m]
Dominique L. Braun,[n] Huldrych F. Günthard,[n] Felix Beuschlein,[m] Anna Conen,[c] Emily West,[n] Egon Isenring,[b] Stefan Zechmann,[a]
Gabriela Bucklar,[a] Yoann Aubry,[a] Ludovic Dey,[f] Beat Müller,[b] Patrick Hunziker,[d] Philipp Schütz,[b] Marco Cattaneo,[e] and
Marc Y. Donath [a*]

www.thelancet.com Vol 53 November, 2022

Interpretation In patients with type 2 diabetes who were hospitalised with COVID-19, treatment with canakinumab in addition to standard-of-care did not result in a statistically significant improvement of the primary composite outcome. Patients treated with canakinumab required significantly less anti-diabetes drugs to achieve similar glycaemic control. Canakinumab was associated with a prolonged reduction of systemic inflammation.

win ratio: the CanCovDia study

components of primary endpoint:

1. survival time
2. ventilation time
3. ICU time
4. hospitalization time

Pocock et al. (2012). The win ratio:
a new approach to the analysis of
composite endpoints in clinical
trials based on clinical priorities.
Eur Heart J 33:176–182.

unmatched win-ratio approach:

- all 57 canakinumab patients compared with all 57 placebo patients (3249 comparisons)
- comparisons of components of primary endpoint combined in **lexicographic order** (winner determined by **first component** in which patients were *known* to differ, up to 4 weeks after study treatment)
- win ratio (number of canakinumab wins divided by number of placebo wins): 1.08, 95% CI [0.69,1.69], p=0.72